Bosenberg, Marcus W. - Yale University - Biological & Biomedical Sciences

个人简介

Marcus Bosenberg M.D., Ph.D., is a physician scientist who directs a leading melanoma research laboratory, is Co-Leader of the Genomics, Genetics and Epigenetics Program of the Yale Cancer Center, Co-Director of the Yale SPORE in Skin Cancer, and is a practicing dermatopathologist at Yale Dermatopathology through Yale Medicine. In his research, Dr. Bosenberg studies the genetics and cellular changes that result in melanoma, the leading cause of skin cancer deaths. His laboratory has developed several widely utilized mouse models in order to study how melanoma forms and progresses, to test new melanoma therapies, and how the immune system can be stimulated to fight melanoma. He works to translate basic scientific findings into improvements in melanoma diagnosis and therapy. He has published over 100 peer-reviewed articles, is a member of the Yale Cancer Center Executive Committee, and is a faculty member of the Raymond and Beverly Sackler Institute for Biological, Physical, and Engineering Sciences. Dr. Bosenberg mentors undergraduate, graduate, medical, and MD-PhD students in his laboratory, teaches at Yale School of Medicine, and trains resident physicians, fellows, and postdoctoral fellows. MD Cornell University Medical College (1994) PhD Cornell University Medical College (1993) BA Cornell University (1986) Research Fellow Dana-Farber Cancer Institute Fellow Harvard Medical School Dermatopathology Training Program Chief Resident Brigham & Women's Hospital Resident Brigham & Women's Hospital Research Fellow University of Wisconsin Board Certification AB of Pathology, Anatomic Pathology (2000) Board Certification AB of Pathology, Dermatopathology (2001)

研究领域

Cell Biology; Dermatology; Melanoma; Neoplasm Metastasis; Pathology

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Genotype-selective combination therapies for melanoma identified by high-throughput drug screening Held MA, Langdon CG, Platt JT, Graham-Steed T, Liu Z, Chakraborty A, Bacchiocchi A, Koo A, Haskins JW, Bosenberg MW*, David F. Stern DF*. Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discovery. 2013, 3:52-67 ß-catenin signaling controls metastasis in BRAF-activated Pten-deficient melanomas Damsky WE, Curley DP, Santhanakrishnan M, Rosenbaum LE, Platt JT, Gould Rothberg BE, Taketo MM, Dankort D, Rimm DL, McMahon M, Bosenberg M. ß-catenin signaling controls metastasis in BRAF-activated Pten-deficient melanomas. Cancer Cell. 2011, 20:741-54. Characterization of melanoma cells capable of propagating tumors from a single cell Held MA, Curley DP, Dankort D, McMahon M, Bosenberg MW. Characterization of melanoma cells capable of propagating tumors from a single cell. Cancer Res. 2010, 70:388-97. BrafV600E cooperates with Pten silencing to induce metastatic melanoma Dankort D*, Curley DP*, Cartilage RA, Nelson B, Karnezis AN, Damsky WE, You MJ, DePinho RA, McMahon M*, Bosenberg M*. BrafV600E cooperates with Pten silencing to induce metastatic melanoma. Nat Genet. 2009, 41:544-52. mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation Damsky W, Micevic G, Meeth K, Muthusamy V, Curley DP, Santhanakrishnan M, Erdelyi I, Platt JT, Huang L, Theodosakis N, Zaidi MR, Tighe S, Davies MA, Dankort D, McMahon M, Merlino G, Bardeesy N, Bosenberg M. mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation. Cancer Cell. 2015, 27:41-56. DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR Micevic G, Muthusamy V, Damsky W, Theodosakis N, Liu X, Meeth K, Wingrove E, Santhanakrishnan M, Bosenberg M. DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR. Cell Rep. 2016, 14:2180-92. Micevic G, Theodosakis N, Taube JM, Bosenberg MW, Rodić N: Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas. Melanoma Res. 2017 Apr. PMID: 27997431 Gayvert KM, Aly O, Platt J, Bosenberg MW, Stern DF, Elemento O: A Computational Approach for Identifying Synergistic Drug Combinations. PLoS Comput Biol. 2017 Jan; 2017 Jan 13. PMID: 28085880 Meeth K, Wang JX, Micevic G, Damsky W, Bosenberg MW: The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations. Pigment Cell Melanoma Res. 2016 Sep; 2016 Aug 3. PMID: 27287723 Lim YH, Fisher JM, Bosenberg MW, Choate KA, Ko CJ: Keratoacanthoma Shares Driver Mutations with Cutaneous Squamous Cell Carcinoma. J Invest Dermatol. 2016 Aug; 2016 Jun 7. PMID: 27283355 Antonov NK, Bosenberg MW, Halasz CL: Melanosis of the areola and nipple with an atypical pigment network. Int J Dermatol. 2016 Jul; 2015 Jul 28. PMID: 26220624 Theodosakis N, Micevic G, Bosenberg MW, Rodić N: Cell and Tissue Display: An Alternative Multipurpose Tool for Microscopy. J Histochem Cytochem. 2016 Jul; 2016 Jun 7. PMID: 27270967 Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA: The state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res. 2016 Jul; 2016 Apr 17. PMID: 27087480 Tinoco R, Carrette F, Barraza ML, Otero DC, Magaña J, Bosenberg MW, Swain SL, Bradley LM: PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion. Immunity. 2016 May 17. PMID: 27192578 Theodosakis N, Micevic G, Sharma R, Baras AS, Lazova R, Bosenberg MW, Rodić N: Integrative discovery of CD98 as a melanoma biomarker. Pigment Cell Melanoma Res. 2016 May; 2016 Apr 10. PMID: 26850337 Odell ID, Lilly E, Reeve K, Bosenberg MW, Milstone LM: Well-Differentiated Syringofibrocarcinoma in a Patient With Clouston Syndrome. JAMA Dermatol. 2016 Apr. PMID: 26792110 Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL Jr, Bosenberg MW, Woodman SE, Overwijk WW, Lizée G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu P: Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 2015 Dec 8. PMID: 26645196 Schartl M, Larue L, Goda M, Bosenberg MW, Hashimoto H, Kelsh RN: What is a vertebrate pigment cell? Pigment Cell Melanoma Res. 2016 Jan; 2015 Nov 3. PMID: 26247887 Langdon CG, Wiedemann N, Held MA, Mamillapalli R, Iyidogan P, Theodosakis N, Platt JT, Levy F, Vuagniaux G, Wang S, Bosenberg MW, Stern DF: SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells. Oncotarget. 2015 Nov 10. PMID: 26485762